No Data
No Data
Express News | Syndax Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Syndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Syndax Pharmaceuticals Restructures Leadership Team
Express News | Syndax Pharmaceuticals Inc - Eliminates Chief Medical Officer Position
Barclays Maintains Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Maintains Target Price $33
Barclays Gives a Buy Rating to Syndax Pharmaceuticals (SNDX)
No Data